Search Results - "Lumry, W."

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update by Maurer, M., Magerl, M., Ansotegui, I., Aygören‐Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W. R., Martinez‐Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez‐Borges, M., Zhi, Y., Zuraw, B., Craig, T.

“…Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global…”
Get full text

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study by Riedl, M. A., Aygören‐Pürsün, E., Baker, J., Farkas, H., Anderson, J., Bernstein, J. A., Bouillet, L., Busse, P., Manning, M., Magerl, M., Gompels, M., Huissoon, A. P., Longhurst, H., Lumry, W., Ritchie, B., Shapiro, R., Soteres, D., Banerji, A., Cancian, M., Johnston, D. T., Craig, T. J., Launay, D., Li, H. H., Liebhaber, M., Nickel, T., Offenberger, J., Rae, W., Schrijvers, R., Triggiani, M., Wedner, H. J., Dobo, S., Cornpropst, M., Clemons, D., Fang, L., Collis, P., Sheridan, W. P., Maurer, M.

“…Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor…”
Get full text

Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial by Malbrán, A., Riedl, M., Ritchie, B., Smith, W. B., Yang, W., Banerji, A., Hébert, J., Gleich, G. J., Hurewitz, D., Jacobson, K. W., Bernstein, J. A., Khan, D. A., Kirkpatrick, C. H., Resnick, D., Li, H., Fernández Romero, D. S., Lumry, W.

“…Summary Hereditary angioedema (HAE) is characterized by potentially life‐threatening recurrent episodes of oedema. The open‐label extension (OLE) phase of the…”
Get full text

Efficacy of Icatibant in Laryngeal Attacks of Type I and II Hereditary Angioedema (HAE): A Pooled Analysis of Three Phase III Trials by Lumry, W, Ritchie, B, Baş, M

Get full text

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma by Busse, William W., Chervinsky, Paul, Condemi, John, Lumry, William R., Petty, Thomas L., Rennard, Stephen, Townley, Robert G.

“…Background: Airway inflammation is a hallmark of asthma, therefore current treatment recommendations include the use of inhaled glucocorticosteroids (GCS)…”
Get full text

Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis by Grubbe, R E, Lumry, W R, Anolik, R

“…Antihistamines are first-line therapy for the treatment of seasonal allergic rhinitis (AR); however, an oral decongestant is often added to improve control of…”
Get full text

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE) by Schranz, J, Levy, R, Lumry, W, Manning, M, Jacobs, J, Dychter, S.S, LaBarre, M.J, Phillips, A, Gelone, S, Broom, C

Get full text

Efficacy and Safety of a Combination of Desloratadine and Pseudoephedrine Compared with Desloratadine or Pseudoephedrine Alone in Subjects with Seasonal Allergic Rhinitis by Anolik, R, Grubbe, R, Lumry, W

“…Rationale Desloratadine (DL), a nonsedating selective H1-receptor antagonist, is efficacious in treating sneezing, rhinorrhea, nasal congestion, and itching…”
Get full text

Interim Results of EDEMA2, a Multicenter, Open-label, Repeat-Dosing Study of Intravenous and Subcutaneous Administration of Ecallantide (DX-88) in Hereditary Angioedema by Lumry, W., Ritchie, B., Beck, T., Morrison, J.

“…Ecallantide (DX-88) is a highly specific, potent inhibitor of human plasma kallikrein that has previously been shown to be promising for safe and effective…”
Get full text

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis by Lumry, William R.

“…The anti-inflammatory activity of corticosteroids has prompted the exploration of their use in the treatment of allergic rhinitis. The development of…”
Get full text

ATTACK LOCATION AND SEVERITY/RESOLUTION IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE); OBSERVATIONS FROM COMMUNITY IMMUNOLOGY by Lumry, W., Li, H., Milligan, S., Raasch, J., Riedl, M.

“…Hereditary angioedema (HAE) symptom severity is highly individualized and differentially debilitating between affected individuals. As a step towards…”
Get full text

Efficacy and Safety of Long-Term Prophylaxis with C1 Inhibitor (C1INH) Concentrate in Patients with Hereditary Angioedema (HAE) by Zuraw, B, Busse, P, White, M, Jacobs, J, Lumry, W, Baker, J, Hurewitz, D, Manning, M, Koleilat, M, Friedman, R.A, Wilkinson, R, Cartwright, W.E, Tanner, D, Kohler, G, Gunther, G

“…The number of discrete angioedema attacks and days of swelling during each arm of the study were summed, and the primary endpoint was the number of attacks on…”
Get full text

SUBSTANTIAL REDUCTION OF HEREDITARY ANGIOEDEMA ATTACK SYMPTOM BURDEN IN THE SEBETRALSTAT PHASE 3 KONFIDENT TRIAL by Lumry, W., Cohn, D., Bernstein, J., Audhya, P., Hao, J., Smith, M., Yea, C., Riedl, M.

“…Although guidelines recommend treating attacks early to avoid symptomatic progression, many people with hereditary angioedema (HAE-C1INH) delay treatment with…”
Get full text

DRUG PATTERNS, CLINICAL OUTCOMES, AND ECONOMIC COSTS AMONG HEREDITARY ANGIOEDEMA PATIENTS INITIATING LONG-TERM PROPHYLAXIS by Kutrieb, E., Weycker, D., Llonch, M. Vera, Zbrozek, A., Harris, A. Claxton, Ottino, K., Lumry, W.

“…This study explores real-world drug use patterns, attack rates, and attack-related healthcare expenditures among patients with hereditary angioedema (HAE)…”
Get full text

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis by Bernstein, David I., Creticos, Peter S., Busse, William W., Cohen, Robert, Graft, David F., Howland, William C., Lumry, William R., Pedinoff, Andrew J., Ratner, Paul H., Lim, Janet, Stokes, Arthur, McNally, Charles

“…Background: Few clinical trials have directly compared the efficacy of antihistamines with topical nasal corticosteroids. Objective: The study was performed to…”
Get full text

SUPPORT FOR STAR-0215 ADMINISTERED EVERY THREE- OR SIX-MONTHS FOR HEREDITARY ANGIOEDEMA: PHASE 1A Results by Morabito, C., Cohen, T., Gunsior, M., Nichols, A., Chung, J., Bernard, K., Gustafson, P., Lumry, W.

“…STAR-0215 is an investigational extended half-life monoclonal antibody for hereditary angioedema (HAE). This trial (NCT05477160) assesses STAR-0215′s potential…”
Get full text

LONG-TERM QUALITY-OF-LIFE AND PATIENT-REPORTED IMPROVEMENTS WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA: PHASE 3 OPEN-LABEL EXTENSION STUDY by Braverman, J., Chapdelaine, H., Sitz, K., Katelaris, C., Guilarte, M., Longhurst, H., Lawo, J., Lumry, W.

“…Hereditary angioedema (HAE) attacks impair quality of life (QoL). Garadacimab (anti-activated factor XII monoclonal antibody) reduced attacks in pivotal Phase…”
Get full text

REASONS NOT TO TREAT HAE ATTACKS AND SATISFACTION FOR ON-DEMAND TREATMENT by Mendivil, J., Anderson, J., Busse, P., Lumry, W., Riedl, M., Earl, L.

“…The notion that HAE patients do not treat all attacks is well known by HAE experts, but it has not been thoroughly documented in literature. Moreover, reasons…”
Get full text

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler by Bernstein, D.I., Berkowitz, R.B., Chervinsky, P., Dvorin, D.J., Finn, A.F., Gross, G.N., Karetzky, M., Kemp, J.P., Laforce, C., Lumry, W., Mendelson, L.M., Nelson, H., Pearlman, D., Rachelefsky, G., Ratner, P., Repsher, L., Segal, A.T., Selner, J.C., Settipane, G.A., Wanderer, A., Cuss, F.M., Nolop, K.B., Harrison, J.E.

“…A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for the treatment of asthma. A 12-week, double-blind,…”
Get full text

SUSTAINED REAL-WORLD ATTACK REDUCTIONS FOLLOWING BEROTRALSTAT INITIATION AMONG PATIENTS WITH HEREDITARY ANGIOEDEMA WITHOUT C1-INHIBITOR DEFICIENCY by Davis-Lorton, M., Tachdjian, R., Lopez-Gonzalez, L., MacKnight, S., Laliberte, F., Martinez, C., Gillard, P., Lumry, W.

“…Hereditary angioedema patients without C1-inhibitor deficiency (HAE-nl-C1-INH) experience potentially life-threatening swelling attacks that characterize HAE…”
Get full text